NYSE:GSK - New York Stock Exchange, Inc. - US37733W2044 - ADR - Currency: USD
2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
---|---|---|---|---|---|---|---|---|
Revenue | 31.38B | 30.33B | 29.32B | 24.70B | 24.35B | |||
Minority Interest Expense | -376.00M | -380.00M | -665.00M | -711.00M | -639.00M | |||
Cost Of Goods | 8.82B | 8.36B | 8.47B | 8.01B | 7.32B | |||
Gross Profit | 22.56B | 21.96B | 20.86B | 16.69B | 17.03B | |||
Operating Expenses | 14.41B | 13.66B | 12.46B | 10.94B | 11.04B | |||
Research and Development | 6.02B | 5.75B | 5.06B | 4.53B | 4.32B | |||
Selling, General, and Administrative Expenses | 8.97B | 9.03B | 8.13B | 6.75B | 7.03B | |||
Operating Income | 8.15B | 8.30B | 8.39B | 5.75B | 5.99B | |||
Interest Income/Expense | -550.00M | -1.29B | -1.44B | -2.36B | -1.62B | |||
Other Income/Expense | N/A | -48.00M | -799.00M | 561.00M | -409.00M | |||
Non Recurring Items | -4.12B | -897.00M | -529.00M | -355.00M | 1.21B | |||
Income Before Taxes | 3.48B | 6.06B | 5.63B | 3.60B | 5.17B | |||
Income Tax | 526.00M | 756.00M | 707.00M | 83.00M | 67.00M | |||
Net Income | 2.58B | 4.93B | 14.96B | 4.38B | 5.75B | |||
EBITDA | 11.13B | 10.60B | 10.54B | 8.13B | 8.35B | |||
Per Share Data | ||||||||
EPS Diluted Total Ops | 1.26 | 2.43 | 7.43 | 2.19 | 2.88 | |||
Non GAAP EPS | 3.72 | 3.15 | 3.00 | 2.87 | 2.93 | |||
Statistics | ||||||||
Gross Profit Margin | 71.90% | 72.42% | 71.13% | 67.58% | 69.94% | |||
Profit Margin | 8.21% | 16.25% | 51.00% | 17.76% | 23.61% | |||
Operating Profit Margin | 25.96% | 27.38% | 28.63% | 23.28% | 24.61% |
All data in GBP